rmed-8k_20220810.htm
false
0001716621
0001716621
2022-08-10
2022-08-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 10, 2022
Ra Medical Systems, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-38677 |
|
38-3661826 |
|
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
2070 Las Palmas Drive
Carlsbad, California 92011
(Address of principal executive offices, including zip code)
(760) 804-1648
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☒ |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which registered |
|
Common Stock, par value $0.0001 per share |
|
RMED |
|
NYSE American |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Amendment to Letter Agreement
On August 10, 2022, Ra Medical Systems, Inc. (the “Company”) and Brian Conn, the Company’s interim Chief Financial Officer, entered into an amendment (the “Amendment”) to the letter agreement dated May 27, 2022 (the “Agreement”). Pursuant to the terms of the Amendment, effective July 27, 2022, the term of the Agreement shall continue for a period of twelve months from June 27, 2022, unless terminated earlier pursuant to the terms of the Agreement. The Agreement shall renew for successive one-month periods on each expiration or renewal date, as applicable, only if mutually agreed to in writing by both parties. Pursuant to the terms of the Amendment, effective July 27, 2022, Mr. Conn will be eligible to receive cash compensation of $20,000 per month for providing services for twenty to thirty hours a week, increased from $10,000 per month for providing services for ten to fifteen hours a week.
The above summary description of Mr. Conn’s Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
RA MEDICAL SYSTEMS, INC. |
|
|
|
|
|
|
|
Date: August 12, 2022 |
|
By: |
|
/s/ Jonathan Will McGuire |
|
|
|
|
|
Jonathan Will McGuire |
|
|
|
|
|
Chief Executive Officer |
|
|
|
|
|
(Principal Executive Officer) |
